Zinc Finger Nucleases (ZFNs) with Sigma's Dave Smoller, Supriya Shivakumar

Podcast Sponsor: Singulex- Watch our cardiovascular monitoring programs explained on YouTube


Dr. Dave Smoller, CSO, Sigma Life Science Bio and Contact Info

Dr. Supriya Shivakumar, Global Marketing Manager, Sigma Life Science Bio and Contact Info

ZFN technology and products Listen (9:42) ZFN technology and products

A game changer Listen (2:09) "A game changer"

Rats better than mice for studying neural diseases Listen (3:42) Rats better than mice for studying neural diseases

Improvement in products Listen (2:12) Improvement in products

Why buy when researchers can make their own? Listen (3:00) Why buy when researchers can make their own?

Revival of gene therapy Listen (6:24) Revival of gene therapy?

Recent study on hemophilia Listen (5:59) Recent study on hemophilia

Applications in AgBio Listen (7:35) Applications in AgBio

If we'd only had ZFN back when Listen (7:55) If we'd only had ZFNs back when . . .

(ZFNs) or Zinc finger nucleases are a class of engineered DNA-binding proteins that enable targeted editing of the genome. They do this by creating double-strand breaks in DNA at virtually any specific location. Through homologous and non-homologous recombination, the technology can generate precisely targeted genomic edits including gene deletions (Knockouts), integrations, or modifications. The technology holds great promise for treating human disease such as hemophilia and sickle cell anemia and may revive gene therapy. In addition the ZFNs are offering new possibilities in plant and animal research. Developed first by Sangamo Biosciences, the technology has been licensed to Sigma Life Science which they offer as their CompoZr ZFN technology.

Here to talk to us about this exciting technology and the promise of its many applications is Dr. Dave Smoller, CSO at Sigma and Supriya Shivakumar, global marketing manager for functional Genomics at Sigma. Dave was formerly president of the Research Biotech Business Unit at Sigma. Before that he founded two companies which were acquired, ProteoPlex, focused on functional genomics and Genome Systems, which offered access to Human Genome project related technologies. Supriya did graduate studies in Harold Varmus’ lab at UC San Francisco, where she used reverse genetics approaches to study oncogenes and their normal biological role in C. elegans.